The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Standardization of ctDNA guide decision-making for MSS mCRC
Giulia Martini, MD, PhD, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, describes the requirement for standardization before circulating tumor DNA (ctDNA) hyperselection can be implemented into routine clinical decision-making for microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). Additional pre-analytic and post-analytic variables could be introduced, thus standardization is required to ensure patients receive consistent molecular selection results. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
